EV-035 is a series of preclinical antibiotic compounds, of which the lead molecule is GC-072. GC-072 has shown efficacy in in vitro and in vivo studies against a wide range of bacterial pathogens, notably Burkholderia pseudomallei. This pathogen causes the disease melioidosis and is regarded as a potential bio-threat agent.

In August 2014 Evolva was awarded a contract by the US Defense Threat Reduction Agency (DTRA) to develop GC-072 as an antibiotic for the treatment of acute Melioidosis to the point of filing an IND.

In December 2014 Evolva sold the EV-035 series to Emergent BioSolutions (Maryland, USA). Evolva received USD 1.5 million from Emergent in 2014 and a further USD 4 million in 2015. If EV-035 progresses through clinical development, Evolva is potentially due clinical and regulatory milestone payments from Emergent of up to USD 65 million and tiered royalties up to a maximum of 10% on net sales.

  • Heinrich Wieland, the biochemist who defied the Nazis

    It might be said that all Nobel laureates are inspirational in their own way. But, if you're also looking for a portrait in courage and cleverness, look no further than the story of biochemist Heinrich Wieland.

    The Guardian
  • Making alliances work

    Evolva believes that good collaborations require good communication, good science and engineering, and of course good results.

    Harvard Bus. Review
More articles

Sign up to receive our
Press Releases!

Sign up